Q2 2025 GlaxoSmithKline Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) reported a revenue growth of 5% in Q2 2024, marking the first time revenue from operations exceeded 1,000 crore.
- The company's general medicine business achieved a volume growth of 6%, with most brands tracking above market growth.
- The vaccines portfolio delivered an 18% growth, with 7% attributed to the Shingrix business.
- EBITDA margins improved by 11%, reaching 32%, supported by stable gross margins and a 4% reduction in the cost base.
- The company declared a special dividend of 12 per share to commemorate 100 years of operations in India.
- The Q2 performance was slightly below expectations due to lower growth momentum in some acute segments.
- There was a sluggish growth in the external market conditions, particularly in the acute segments compared to chronic ones.
- The company faced an unfavorable pricing component, with growth primarily driven by volume rather than price.
- There was a delay in aligning functional swim lanes for the launch of two oncology assets, causing some setbacks.
- The vaccines segment saw a drop in unit and value growth as per IPM data in the last 2 to 3 months.
Ladies and gentlemen, good day and welcome to the Glaxo Smith Kline Pharmaceuticals Limited Q2 earnings analyst conference call. (Operator Instructions). I now hand the conference over to Mr. Bhushan Akshikar. Thank you and over to you, sir.
Thank you very much for setting this up. A very, very good afternoon to everybody on the call in the next 20 minutes or so. I and the UVR CFO will take us through the results for Q2 of 2024. And before we dive deep, dive into the financials, I want to begin by wishing everyone a very happy hunter just at the cusp of celebrating Diwali. So wish you the very best and a very prosperous Diwali to all of us. Can we move to the next slide?
So we just concluded our board meeting this afternoon and before we go and look at the specifics on the financials, just want to contextualize our performance, our competitive performance. As we see it reflected in the external data sources. As each one of you is aware, we continue to be a broadly
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
